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Background. Patients with abdominal aortic aneurysm (AAA) can be treated by transfemoral endovascular intervention
and by conventional open surgery. Level-one evidence of the safety and efficacy of one treatment mode over the other is only
provided by a randomised controlled trial (RCT). Results reported by voluntary registries are considered less valid than
data from RCTs. On the other hand the outcome of a RCT may not be generalisable to the common practice because of
vigorous selection of patients and institutions.
Purpose. The outcomes reported by the Dutch Randomized Endovascular Aneurysm Management (DREAM) trial were
compared with the results of the EURopean collaborators on Stent-graft techniques for AAA Repair (EUROSTAR)
registry.
Methods. To obtain comparable study groups with regard to risk factors equal proportions of ASA I, II and III patients as
observed in the endovascular arm of the DREAMtrial were selected at random from the EUROSTAR-registry. All patients
had an aneurysm of at least 50 mm. Only patients, who had been enrolled into the registry from 1999, were selected to
avoid the influence of first generation endografts which are not longer in use. Patient characteristics and outcomes of
endovascular AAA repair (EVAR) of EUROSTAR and DREAM-trial participants were compared. Differences in early
findings between study groups were assessed by Chi-Square tests for discrete variables and by Wilcoxon rank sum tests
for continuous variables. Follow-up variables were analysed by Kaplan-Meier and Cox proportional hazard models.
Results. Data of 177 patients of the DREAM trial with randomization to EVAR and 856 patients selected in the EUROSTAR-
registry were compared. Baseline characteristics were comparable between the EUROSTAR-cohort and EVAR-arm of the
DREAM-trial. The 36-month survival-rate was 87.6% for EVAR-arm in the DREAM-trial similar to the 86.8% found in
this EUROSTAR-study population. The freedom of secondary procedures reached after 3 years 85.7%, and 86.9% in the
DREAM and EUROSTAR-cohort, respectively.
Conclusion.We found comparable characteristics and outcomes between patients of comparable risk class of the EUROSTAR-
registry and the EVAR-cohort of the DREAM-trial. This demonstrates the following: first, the EUROSTAR-data provide
reliable information, and further comparisons of registry data with patients treated by conventional AAA surgery may be
justified. Secondly, the various outcomes of the randomised DREAM trial appear generalisable, as it agrees with observa-
tions in a broad common practice derived database.
Keywords: Study design; Randomized clinical trial; Observational registry; Abdominal aortic aneurysm; Endovascular
repair; DREAM; EUROSTAR.Introduction
A randomised controlled trials (RCT) is generally ac-
cepted as the best possible evidence to indicate the
value of an intervention. A prospective definition of
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of outcomes and unbiased selection of subjects and
controls are indispensable for scientifically sound
comparison. RCTs are carefully crafted experiments
that provide evidence on the benefit of a specific
health intervention only under strictly controlled
study conditions. Because of differences in conditions,
a health benefit observed in a RCT may not necessar-
ily be maintained when the intervention is introduced
into routine clinical practice.1e3
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EUROpean collaborators on Stent-graft Techniques
for Abdominal aortic aneurysm Repair (EUROSTAR)
registry and the Dutch Randomized Endovascular
Aneurysm Management (DREAM) trial. A cohort
from the EUROSTAR registry was stratified with
a comparable ASA physical status classification distri-
bution as the endovascularly treated cohort recruited
in the DREAM-trial. The characteristics and outcomes
of this EUROSTAR-cohort were compared to these of
the EVAR-cohort of the DREAM-trial to analyse any
differences or similarities. To avoid bias from smaller
series or incomplete reporting of follow-up only cen-
ters with the best compliance to the registry recruit-
ment and follow-up schedule were selected for this
comparison.
Methods
The randomized clinical DREAM-trial commenced in
2000. Patients referred to clinics departments of vas-
cular surgery at 24 centers in the Netherlands and 4
centers in Belgium participated in the trial (Appendix).
All patients were diagnosed with an AAA of at least
5 cm, were considered suitable candidates for either
endovascular or open repair, and were randomly
assigned to receive one of these treatments.4
The EUROSTAR-project is a voluntary multicenter
registry, which was established in 1996.5 Of a total
of 2696 patients enrolled in the registry by the ‘‘top
centers’’ (Appendix). The centers in this analysis
were selected on the basis of their follow-up compli-
ance and enrolled patient volume. The selected cen-
ters were still active participating in the EUROSTAR
registry, enrolled at least 50 patients treated with
modern devices, and the follow-up compliance had
to be minimal 80%. We stratified a patient group
from this selected EUROSTAR-cohort with a compara-
ble distribution of ASA physical status classification as
the patient group included in EVAR arm of the DREAM-
trial (21% ASA I, 71% ASA II, and 8% ASA III).6 All
patients with ASA I enrolled in the EUROSTAR reg-
istry were selected (N¼ 180). Subsequently a random
sample of 605 patients with ASA II and 71 with ASA
III were selected. No patients with ASA IV were se-
lected as this category was excluded for participation
in the DREAM-trial. All patients in the present study
group had an aneurysm of at least 50 mm. Only pa-
tients, who had been enrolled into the registry from
1999, were selected to avoid the influence of first gen-
eration withdrawn types of devices. Completeness of
follow-up in this selected cohort at 1, 3, 5 year was
97.6%, 98.6% and 99.9%, respectively.The 856 selected patients of the EUROSTAR-cohort
where compared to the 177 patients of the EVAR-arm
of the DREAM-trial. Differences in findings between
study groupswere assessed byChi-Square tests for dis-
crete variables and byWilcoxon rank sum tests for con-
tinuous variables. Kaplan-Meier analysis was used for
survival analysis. Multivariate Cox models were used
to determine whether baseline and follow-up variables
were independently associatedwith adverse outcomes.
A p-value of 0.05 or less was considered as statistical
significant. Data was analysedwith SAS statistical soft-
ware, version 8.02 (SAS Institute).
Results
There were 165 men and 12 women in the EVAR-arm
of the DREAM-trial, with a median age of 70.6 years.
The selected EUROSTAR-cohort consisted of 856 pa-
tients of which 793 men with a mean age of 71.6 years.
There were no major differences in demographic,
morphologic and operative characteristics at baseline
between the EUROSTAR-cohort and the EVAR-arm
of the DREAM-cohort (Tables 1e3).
The most frequently reported risk factors were hy-
pertension and a history of cardiac disease. In the
EUROSTAR-cohort fewer patients were current
smokers or had smoked in the past 10 years (48.4%
vs. 63.9%, p¼ .0003). The mean maximal aneurysm
diameter was approximately 60 mm, in both groups.
However, the distribution of aneurysm morphology
classes regarding aneurysmal involvement of the iliac
arteries differed between the study populations. The
most frequently occurring aneurysm morphology
class was B in both study groups. In the EUROSTAR-
cohort a larger proportion class A aneurysms were in-
cluded (15.9% vs. 7.0%, p¼ .0025). Most patients were
treated with a bifurcated stent-graft (93-94%). Regional
anaesthesia was used in a higher proportion in the
DREAM-trial (40.7% vs. 29.0%, p¼ .0022).
The operative mortality was 2.0% in the EUROSTAR-
cohort versus 1.2% in the EVAR arm of the DREAM-
trial ( p¼NS) (Table 3). Moderate and severe systemic
complications were reported in 9.3% vs. 11.7%, and
local complications in 10.6% vs. 16.4%, in the
EUROSTAR and DREAM-cohort, respectively (Table 4).
Overall 84 patients died in the EUROSTAR-cohort
and 31 in the DREAM-cohort. Within a follow-up pe-
riod of 3 years the survival-rate in the DREAM-trial
(87.6%) was comparable with the EUROSTAR-cohort
(86.8%). Secondary interventions were required in 85
and 21 patients of the EUROSTAR and DREAM-
cohort, respectively. The freedom of secondary proce-
dures reached after 3 years 85.7% and 86.9% in theEur J Vasc Endovasc Surg Vol 33, February 2007
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we noticed the comparability between the EVAR-arm
of the DREAM-trial and the EUROSTAR-cohort. In
the EUROSTAR-cohort, with longer follow-up time,
a cumulative survival rate of 83.2% and 82.5% was
documented after 4 and 5 years of follow-up, respec-
tively. The freedom from secondary interventions
drops to 83.9% after 4 years of follow-up.
Multivariate analysis of demonstrated an associa-
tion between a higher mortality and advanced aged
(HR¼ 1.06, 95%CI¼ 1.03e1.09, p< .0001), baseline
pulmonary impairment (HR¼ 1.74, 95%CI¼ 1.19e
2.54, p¼ .0046), and larger aneurysm diameter at
baseline (HR¼ 1.02, 95%CI¼ 1.01e1.04, p¼ .0091). The
only independent variable influencing the secondary
intervention rate was advanced age (HR¼ 1.03,
95%CI¼ 1.00e1.07, p¼ .0363). These hazard rates are
mainly influenced by the larger number patients
Table 1. Baseline characteristics of the patients
EUROSTAR
N¼ 856
DREAM
N¼ 177
P-
value
Age (years) 71.60 7.67 70.61 6.51 NS
Male sex 793 (92.6) 165 (93.2) NS
Moderate/Severe SVS/AAVS risk scorey
Diabetes 88 (10.3) 19 (10.7) NS
Smoking 414 (48.4) 113 (63.9) .0003
Hypertension 488 (57.0) 104 (58.8) NS
Hyperlipemia 331 (38.7) 81 (45.8) NS
Carotid disease 75 (11.6) 27 (15.3) NS
Cardiac disease 390 (45.6) 75 (42.4) NS
Renal disease 89 (10.4) 13 (7.3) NS
Pulmonary disease 211 (24.7) 48 (27.1) NS
Sum of SVS/AAVS
risk-factor scorez
3.18 2.58 3.51 2.65 NS
ASA-class#
I 180 (21.0) 38 (21.5) NS
II 605 (70.7) 125 (70.6) NS
III 71 (8.2) 14 (7.9) NS
Previous Laparotomy 206 (24.3) 43 (25.1) NS
Maximal diameter
of aneurysm (mm)
60.37 10.25 60.56 8.93 NS
Aneurysm morphology class*
A 135 (15.9) 12 (7.0) .0025
B 484 (57.0) 114 (66.7) .0193
C 125 (14.7) 16 (9.4) NS
D 62 (7.3) 14 (8.2) NS
E 43 (5.1) 15 (8.8) NS
Continuous data presented as mean standard deviation; categori-
cal data are given as the count (percentage).
y Risk score reporting adhered to the guidelines of the Society
for Vascular Surgery/American Association for Vascular Surgery
(SVS/AAVS).9 Moderate/Severe SVS/AAVS score was defined as
a score 1.
z Sum of all eight recorded SVS risk scores. Each risk score repre-
sented as a value between 0 and 3, according to increasing severity
level.
# ASA: American Society of Anesthesiologists.
* N¼ 849 and 171 for EUROSTAR and DREAM cohort, respec-
tively. Description of the classification of the aneurysm morphology
occurred by size of the aneurysm and aneurysmal involvement of
the iliac artery.5Eur J Vasc Endovasc Surg Vol 33, February 2007enrolled in the EUROSTAR registry. When analysing
the two study groups separately we noticed that previ-
ously observed associations were confirmed in the
EUROSTAR subgroup. In the DREAM-cohort survival
was associatedwith advanced age (HR¼ 1.14, 95%CI¼
1.07e1.23, p¼ .0002) and diabetes mellitus (HR¼ 4.46,
95%CI¼ 1.41e14.05, p¼ .0107). For secondary inter-
vention rate no association could be found.
Discussion
For epidemiologic assessments of the effects of treat-
ments on outcomes different study designs can be
used. Studies can be organised as a randomized clin-
ical trial (RCT) or as an observational study. In the
Table 2. Characteristics of aneurysm-repair procedure
EUROSTAR N¼ 856 DREAM N¼ 177 P-value
N (%) N (%)
Type of anaesthesia
General 524 (61.2) 95 (53.7) NS
Regional 248 (29.0) 72 (40.7) .0022
Local 84 (9.8) 10 (5.6) NS
Type of stent-graft
Bifurcated 832 (92.9) 167 (94.4) NS
Aorto-uni-iliac 46 (5.2) 7 (4.0) NS
Straight tube 10 (1.2) 1 (0.6) NS
Unknown 6 (0.7) 2 (1.1) NS
Brand of endograft
Zenith 310 (36.2) 59 (33.3) NS
Talent 333 (38.9) 49 (27.7) .0049
Excluder 77 (9.0) 37 (20.9) <.0001
AneuRx 77 (9.0) 12 (6.8) NS
Lifepath 3 (0.4) 4 (2.3) .0048
Endologix 7 (0.8) 1 (0.6) NS
Fortron 23 (2.7) 8 (4.5) NS
EVT 5 (0.6) 5 (2.8) .0056
Anaconda 21 (2.4) e .0046
Unknown e 2 (1.1) .0008
Table 3. Surgical and postoperative data
EUROSTAR
N¼ 856
DREAM
N¼ 177
P-
value
Duration of surgery - min
Mean SD 123.65 50.02 194.46 65.70 <.0001
Median 120 180
Interquartile range 90e150 155e220
Duration of hospitalisation
Mean SD 5.38 7.84 5.76 5.64 NS
Median 4 4
Interquartile range 3e5 3e6
Replaced blood volume (ml)
Mean SD 62.51 299.29 99.52 488.29 NS
Median 0 0
Interquartile range 0e0 0e0
Operative Mortality N (%) 17 (2.0) 2 (1.2) NS
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the best quality evidence in medical research. How-
ever, an RCT requires an enormous commitment and
input from the investigators, participants, and pa-
tients. These trials are also costly enterprises, fre-
quently paid out of public resources. For these
reasons, investigators should always make a balanced
decision of the type and conduct of their research
setup. Observational studies are often viewed as hav-
ing less validity because they reportedly overestimate
treatment effects. An observational study usually in-
cludes patients with a large variety of coexisting ill-
ness and a wider spectrum of disease severity. In
contrast, a RCT studies a distinct group of patients
as a result of strictly defined inclusion and exclusion
criteria regarding coexisting pathology and severity
of disease. An experimental protocol may not be rep-
resentative of the wider spectrum of comorbid condi-
tions typically for the current clinical practice.1e3
In the current report we analysed characteristics
and outcomes of endovascular AAA treatment of pa-
tients in the DREAM-trial and patients enrolled in the
EUROSTAR-registry with comparable inclusion crite-
ria.6,7 It should be noted that the registry as a whole
includes a much broader spectrum of patients than
was used in this analysis. In the overall registry 50%
of the patients are at high medical and operative
risk with an ASA-classification of III or IV.
We found similar baseline and surgical characteris-
tic between the selected EUROSTAR-cohort and the
DREAM-trial-patients. Operative mortality was iden-
tical in both study groups. During the first three years
of follow-up also similar survival rates were observed
in the EUROSTAR-cohort and EVAR-arm of the
DREAM trial. Mortality in the EUROSTAR-cohort
was associated independently with advanced age,
pulmonary status and aneurysm size. While in the
DREAM-cohort death was associated with advanced
aged and diabetes mellitus.
It has been suggested that registries tend to over-
estimate the better outcome of the new introduced
treatment. This view is arguable as recently was em-
phasized in two reports.1,2 These reports concluded
Table 4. Complications
EUROSTAR
N¼ 856 N (%)
DREAM
N¼ 177 N (%)
P-value
Endoleak 1876 (20.6) 27 (15.6) NS
Type 1 31 (3.6) 5 (2.8) NS
Type 2 131 (15.3) 19 (10.7) NS
Type 3 15 (1.8) 2 (1.1) NS
Early Moderate/Severe complications
Local e Vascular
implant related
91 (10.6) 28 (16.4) .0490
Systemic 820 (9.3) 20 (11.7) NSon the basis of several comparisons that results of
well-designed observational studies do not systemat-
ically overestimate the magnitude of the effects of
treatment, as compared to RCTs assessing the same
research question and with similar criteria to select
study subjects. With regard to patient characteristics,
mortality and secondary procedure data we can sup-
port this more recent opinion. Blankensteijn et al.
concluded on the basis of a large overview of the
literature on treatment outcomes of AAA, that regis-
tries are accurate in documenting death, but unreli-
able with respect to postoperative morbidity.8 Our
analysis of the complications as recorded by the
EUROSTAR and DREAM revealed a similar fre-
quency of secondary interventions, early endoleaks
and complications in the registry than in the trial. In
the EUROSTAR-cohort the secondary intervention
rate was associated with advanced age, while no asso-
ciation was observed in the DREAM-cohort.
In conclusion, we found similar characteristics and
outcomes in patients with comparable risk class pro-
files enrolled in the EUROSTAR and the EVAR-arm of
the DREAM-trial. This demonstrated in the first place
the accuracy of the EUROSTAR-data. Comparisons
with conventionally treated patients and outcomes of
the EUROSTAR registry appeared valid. Secondly,
and equally important, the outcomeof theDREAMtrial
appeared generalisable, as it agrees with findings in
a broad common practice derived database.
Appendix
DREAM Participating centers:
BELGIUM: St Jozef Hospital Turnhout; St. Trudo Hos-
pital St. Truiden; University Hospital Antwerpen; Univer-
sity Medical Center Gent.
THE NETHERLANDS: Catharina Hospital Eind-
hoven; University Medical Center Utrecht; Academic
Medical Center Amsterdam; Erasmus Medical Center
Rotterdam; University Hospital Groningen; St. Francis-
cus Gasthuis Rotterdam; Rijnstate Hospital Arnhem;
Leyenburg Hospital’s Gravenhage; Albert Schweitzer Hos-
pital Dordrecht; Atrium MedicalCenter Heerlen; MC
Rijnmond Zuid Rotterdam; Jeroen Bosch Hospital den
Bosch; St. Elisabeth Hospital Tilburg; Maxima Medical
Center Veldhoven; OLVG, Amsterdam; Meander Medi-
cal Center Amersfoort; Vlietland Hospital Schiedam;
University Medical Center Nijmegen; Martini Hospital
Groningen; MC Haaglanden’s Gravenhage; Hospital
Bernhoven Oss; Oosterschelde Hospital Goes. VU Medical
Center Amsterdam; Leiden University Medical Center;
University Medical Center Maastricht; Bronovo Hospital’s
Gravenhage.Eur J Vasc Endovasc Surg Vol 33, February 2007
176 L. J. Leurs et al.EUROSTAR Participating centers in current study:
BELGIUM: Onze Lieve Vrouwe Ziekenhuis Aalst; St.
Augustinus Hospital Antwerpen; A.Z.Sint Blasius Den-
dermonde; Universitair Ziekenhuis Gent; Universitair
Ziekenhuis Leuven;AZ Vesalius Tongeren.
GERMANY: Stadtischen Kliniken Frankfurt.
IRELAND: St. James Hospital Dublin.
NORWAY: Aker Hospital Oslo; University Hospital of
Trondheim.
SWITZERLAND: Clinic for Cardiovascular Surgery
Bern.
THE NETHERLANDS: Rijnstate Ziekenhuis Arnhem;
Catharina Ziekenhuis Eindhoven; Medisch Spectrum Twente
Enschede; Universitair Medisch Centrum Groningen; Cani-
sus-Wilhelmina ZiekenhuisNijmegen; Isala KliniekenZwolle.
UNITED KINGDOM: Royal University Hospital
Liverpool; Freeman Hospital NorthernVascular Centre New
Castle-Upon-Tyne.
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